Sinopharm Group Co. Ltd Capital Reinvestment Ratio
Sinopharm Group Co. Ltd capital reinvestment ratio. Sinopharm Group Co. Ltd (X2S) has a Capital Reinvestment Ratio of 0.01x as of December 2022, meaning it reinvests 0% of its operating cash flow (€52.39 Billion) in capital expenditures (€654.69 Million). Check X2S capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Sinopharm Group Co. Ltd (2013–2025)
Capital reinvestment ratio of Sinopharm Group Co. Ltd from 2013 to 2025. This chart tracks Sinopharm Group Co. Ltd's Capital Reinvestment Ratio across 13 annual periods. Also explore Sinopharm Group Co. Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Sinopharm Group Co. Ltd Capital Reinvestment Ratio by Year (2013–2025)
Sinopharm Group Co. Ltd capital reinvestment ratio by year from 2013 to 2025. For the full cash flow conversion analysis, see Sinopharm Group Co. Ltd cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.11x | €14.14 Billion | €1.62 Billion | ▼ -32.9% |
| 2024 | 0.17x | €11.55 Billion | €1.97 Billion | ▲ +25.3% |
| 2023 | 0.14x | €17.17 Billion | €2.34 Billion | ▲ +34.1% |
| 2022 | 0.10x | €20.96 Billion | €2.13 Billion | ▼ -54.5% |
| 2021 | 0.22x | €9.31 Billion | €2.07 Billion | ▲ +31.0% |
| 2020 | 0.17x | €11.15 Billion | €1.90 Billion | ▲ +44.8% |
| 2019 | 0.12x | €18.78 Billion | €2.21 Billion | ▼ -86.8% |
| 2018 | 0.89x | €3.65 Billion | €3.24 Billion | ▲ +34.2% |
| 2017 | 0.66x | €3.21 Billion | €2.12 Billion | ▲ +348.6% |
| 2016 | 0.15x | €9.26 Billion | €1.36 Billion | ▲ +93.6% |
| 2015 | 0.08x | €13.41 Billion | €1.02 Billion | ▼ -70.8% |
| 2014 | 0.26x | €5.56 Billion | €1.45 Billion | ▲ +14.2% |
| 2013 | 0.23x | €4.94 Billion | €1.13 Billion | — |